Teva Pharmaceutical Industries Limited

As of June 30, 2026, Teva Pharmaceutical Industries Limited carries a market capitalization of 39.48B, placing it among publicly traded companies globally. Its enterprise value stands at 52.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Teva Pharmaceutical Industries Limited's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Teva Pharmaceutical Industries Limited has 1.17B shares outstanding.

As of June 30, 2026, Teva Pharmaceutical Industries Limited trades at a trailing price-to-earnings ratio of 55.39. The price-to-sales ratio is 2.26, and the price-to-book ratio stands at 5.09.

As of June 30, 2026, Teva Pharmaceutical Industries Limited trades at an EV/EBITDA multiple of 20.33 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.04 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 32.88 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Teva Pharmaceutical Industries Limited trades at an EV/FCF ratio of 23.64, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 52.70B versus a market cap of 39.48B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Teva Pharmaceutical Industries Limited maintains a current ratio of 0.88, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 217.53, indicating elevated leverage, while an interest coverage ratio of 2.89 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Teva Pharmaceutical Industries Limited posted a return on equity (ROE) of 9.68, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.45 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.77, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.48, useful for judging operating efficiency across full business cycles. The company generates approximately 508,468.85 in revenue per employee across its workforce of 34,051.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.45 indicates how many times Teva Pharmaceutical Industries Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Teva Pharmaceutical Industries Limited recorded 12.00M in income tax expense. That works out to an effective tax rate of 1.69, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 708.00M, leaving 706.00M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Teva Pharmaceutical Industries Limited's stock has gained approximately 111.97% over the past 52 weeks. The 50-day moving average sits at 38.63, while the 200-day moving average is 34.34.

Over the twelve months ended June 30, 2026, Teva Pharmaceutical Industries Limited generated 17.31B in revenue and converted that into 706.00M in net income, yielding earnings per share of 0.60. EBITDA reached 2.59B, while operating income came in at 3.25B.

As of June 30, 2026, Teva Pharmaceutical Industries Limited holds 3.66B in cash and equivalents against 16.87B in total debt, resulting in a net debt position of 12.94B. Total book value stands at 7.75B, with working capital of -1.89B providing operational flexibility.

Teva Pharmaceutical Industries Limited produced 1.90B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -550.00M in capital expenditures, free cash flow totaled 1.35B - equivalent to 1.17 per share.

Over the twelve months ended June 30, 2026, Teva Pharmaceutical Industries Limited posted a gross margin of 52.45, reflecting its pricing power and cost economics. The operating margin of 18.78 and net profit margin of 4.08 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 3.40, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.02, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Teva Pharmaceutical Industries Limited shareholders.

Teva Pharmaceutical Industries Limited's most recent stock split took place on July 1, 2004 with a 1:2 split ratio.

As of June 30, 2026, Teva Pharmaceutical Industries Limited has an Altman Z-Score of 1.04, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.